Key Companies Leading Innovation and Growth in the Gastrointestinal Over-The-Counter (OTC) Drugs Market

The gastrointestinal over-the-counter (OTC) drugs market is poised for notable expansion over the coming years, driven by several important factors. With increasing consumer focus on digestive health and convenient medication options, this sector is attracting growing attention from both manufacturers and buyers. Let's explore the market's size, key players, emerging trends, and the main segments shaping its future.

Market Growth and Outlook for the Gastrointestinal Over-The-Counter Drugs Market
The gastrointestinal OTC drugs market is forecasted to grow steadily, reaching a valuation of $73.3 billion by 2030. This corresponds to a compound annual growth rate (CAGR) of 8.1%. The expansion is propelled by broader adoption of preventive digestive care, the rise of e-commerce channels, increasing demand for clean-label products, an aging population, and heightened awareness around digestive wellness. Key trends expected to influence the market include a surge in self-medication for digestive issues, stronger preference for quick-acting OTC relief, increased use of combination gastrointestinal formulations, growth of online pharmacy sales, and a rising inclination towards herbal and enzyme-based remedies.

Download a free sample of the gastrointestinal over-the-counter (otc) drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24547&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Major Participants Leading the Gastrointestinal Over-The-Counter Drugs Market
Several well-established companies play a dominant role in this market. Noteworthy names include Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Boehringer Ingelheim GmbH, Haleon plc, Sandoz AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, and Dr. Reddy's Laboratories Ltd.

Significant Acquisition Moves in the Market
In July 2024, Cooper Consumer Health SAS, a consumer healthcare company based in France, acquired the Over-the-Counter (OTC) business of Viatris Inc. for an undisclosed sum. This acquisition is expected to double Cooper Consumer Health's revenue and strengthen its footprint across major European markets. The deal adds over 200 well-known OTC brands in areas such as feminine hygiene, antiseptics, and cholesterol management. Viatris Inc., headquartered in the US, specializes in gastrointestinal OTC medications and has been an important player in this sector.

View the full gastrointestinal over-the-counter (otc) drugs market report:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-over-the-counter-otc-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Impacting the Gastrointestinal OTC Drugs Market
Leading companies are increasingly focusing on innovative products like OTC proton pump inhibitors (PPIs) that offer effective and sustained relief from acid-related digestive conditions. These medications, which reduce stomach acid production, are popular for managing heartburn, acid reflux (GERD), and gastric ulcers.
For example, in March 2025, Eisai Co., Ltd., a pharmaceutical company based in Japan, received regulatory approval to reclassify its Pariet S (rabeprazole sodium 10 mg) from prescription-only to an OTC product. This makes it the first OTC PPI in Japan with the same active ingredient and dosage as the prescription version. Pariet S is used to relieve stomach discomfort, heartburn, and bloating, providing 24-hour relief through a once-daily tablet. This development reflects growing demand for effective gastric acid treatments driven by lifestyle changes and demographic shifts.

Detailed Breakdown of the Gastrointestinal OTC Drugs Market Segments
This market is segmented in various ways to better understand product types, formulations, indications, distribution channels, and end users. The main categories include:
1) Product Types: Antacid, Laxatives, Anti-Diarrheal, Anti-Emetics, and Other Products
2) Formulations: Tablets, Capsules, Liquids, and Other Forms
3) Indications: Heartburn, Diarrhea, Constipation, Gastroesophageal Reflux Disease (GERD), Nausea, Vomiting, Motion Sickness, and Additional Conditions
4) Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other Outlets
5) End-User Groups: Hospitals, Clinics, Home Healthcare, and Others

Subcategories within these segments include:
- Antacids such as Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Calcium Carbonate, Magnesium Hydroxide, Sodium Bicarbonate, and Combination Antacids
- Laxatives including Bulk-Forming, Stimulant, Osmotic, Stool Softeners, and Lubricant Types
- Anti-Diarrheals like Loperamide, Bismuth Subsalicylate, Probiotics, and Electrolyte Solutions
- Anti-Emetics comprising Antihistamines, Bismuth Subsalicylate, Phosphorated Carbohydrate Solution, and Ginger Supplements
- Other Products featuring Digestive Enzymes, Simethicone, Herbal Remedies, and Activated Charcoal

This comprehensive segmentation highlights the diversity of products and options available in the gastrointestinal OTC drugs market, catering to a wide range of consumer needs and preferences.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.